Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | MAG | P20916 | 1/20 | 0.36 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | GJB2 | P29033 | 1/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.33 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13381052 | 0.92 | LMNA (0.45) | LMNACYP2D6 | |
| SCHEMBL13381067 | 0.92 | GJB2 (0.43) | PTPN2PTPN1LMNATACR2GJB2 | |
| SCHEMBL13381064 | 0.87 | NT5E (0.36) | PTPN2PTPN1LMNAGJB2NT5E | |
| SCHEMBL13381058 | 0.85 | LMNA (0.41) | LMNACYP2D6 | |
| SCHEMBL13381053 | 0.85 | LMNA (0.38) | LMNACYP2D6 | |
| SCHEMBL13381060 | 0.84 | PTPN1 (0.47) | PTPN2PTPN1BCHEGJB2NT5E | |
| SCHEMBL13381070 | 0.81 | NT5E (0.33) | PTPN2PTPN1LMNAGJB2NT5E | |
| SCHEMBL13381078 | 0.81 | LGALS8 (0.35) | LGALS8LGALS9LMNASLC6A2LGALS3 | |
| SCHEMBL13381069 | 0.81 | TNF (0.35) | LGALS8PTPN2PTPN1LMNAGJB2 | |
| SCHEMBL13381081 | 0.78 | PTPN1 (0.38) | PTPN2PTPN1LMNAGJB2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | ENDOTIS PHARMA (FR) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | SERPINC1, F2, FUT5 | LGALS8 198/4885PTPN2 1229/4885PTPN1 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.